tetano
Editor, Senior Moderator
BMC Pulm Med
. 2023 Aug 26;23(1):310.
doi: 10.1186/s12890-023-02605-2. Days spent on non-invasive ventilation support: can it determine when to initiate VV- ECMO? Observational study in a cohort of Covid-19 patients
María P Fuset-Cabanes[SUP] 1 [/SUP], LLuisa Hernández-Platero[SUP] 1 2 [/SUP], Joan Sabater-Riera[SUP] 1 [/SUP], Miguel Gordillo-Benitez[SUP] 1 [/SUP], Fabio Di Paolo[SUP] 1 [/SUP], Paola Cárdenas-Campos[SUP] 1 [/SUP], Krystel Maisterra-Santos[SUP] 1 [/SUP], María Pons-Serra[SUP] 1 [/SUP], Paola Sastre-Pérez[SUP] 1 [/SUP], Alejandro García-Zaloña[SUP] 1 [/SUP], Javiera Puentes-Yañez[SUP] 1 [/SUP], Xosé Pérez-Fernández[SUP] 3 [/SUP]
Affiliations
Background: The study evaluates the impact of the time between commencing non-invasive ventilation (NIV) support and initiation of venovenous extracorporeal membrane oxygenation (VV-ECMO) in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome (ARDS).
Methods: Prospective observational study design in an intensive Care Unit (ICU) of a tertiary hospital in Barcelona (Spain). All patients requiring VV-ECMO support due to COVID-19 associated ARDS between March 2020 and January 2022 were analysed. Survival outcome was determined at 90 days after VV-ECMO initiation. Demographic data, comorbidities at ICU admission, RESP (respiratory ECMO survival prediction) score, antiviral and immunomodulatory treatments received, inflammatory biomarkers, the need for vasopressors, the thromboprophylaxis regimen received, and respiratory parameters including the length of intubation previous to ECMO and the length of each NIV support (high-flow nasal cannula, continuous positive airway pressure and bi-level positive airway pressure), were also collated in order to assess risk factors for day-90 mortality. The effect of the time lapse between NIV support and VV-ECMO on survival was evaluated using logistic regression and adjusting the association with all factors that were significant in the univariate analysis.
Results: Seventy-two patients finally received VV-ECMO support. At 90 days after commencing VV-ECMO 35 patients (48%) had died and 37 patients (52%) were alive. Multivariable analysis showed that at VV-ECMO initiation, age (p = 0.02), lactate (p = 0.001), and days from initiation of NIV support to starting VV-ECMO (p = 0.04) were all associated with day-90 mortality.
Conclusions: In our small cohort of VV-ECMO patients with COVID-19 associated ARDS, the time spent between initiation of NIV support and VV-ECMO (together with age and lactate) appeared to be a better predictor of mortality than the time between intubation and VV-ECMO.
Keywords: ARDS; COVID-19; Extracorporeal membrane oxygenation; Non-invasive ventilation; Respiratory insufficiency.
. 2023 Aug 26;23(1):310.
doi: 10.1186/s12890-023-02605-2. Days spent on non-invasive ventilation support: can it determine when to initiate VV- ECMO? Observational study in a cohort of Covid-19 patients
María P Fuset-Cabanes[SUP] 1 [/SUP], LLuisa Hernández-Platero[SUP] 1 2 [/SUP], Joan Sabater-Riera[SUP] 1 [/SUP], Miguel Gordillo-Benitez[SUP] 1 [/SUP], Fabio Di Paolo[SUP] 1 [/SUP], Paola Cárdenas-Campos[SUP] 1 [/SUP], Krystel Maisterra-Santos[SUP] 1 [/SUP], María Pons-Serra[SUP] 1 [/SUP], Paola Sastre-Pérez[SUP] 1 [/SUP], Alejandro García-Zaloña[SUP] 1 [/SUP], Javiera Puentes-Yañez[SUP] 1 [/SUP], Xosé Pérez-Fernández[SUP] 3 [/SUP]
Affiliations
- PMID: 37626354
- DOI: 10.1186/s12890-023-02605-2
Background: The study evaluates the impact of the time between commencing non-invasive ventilation (NIV) support and initiation of venovenous extracorporeal membrane oxygenation (VV-ECMO) in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome (ARDS).
Methods: Prospective observational study design in an intensive Care Unit (ICU) of a tertiary hospital in Barcelona (Spain). All patients requiring VV-ECMO support due to COVID-19 associated ARDS between March 2020 and January 2022 were analysed. Survival outcome was determined at 90 days after VV-ECMO initiation. Demographic data, comorbidities at ICU admission, RESP (respiratory ECMO survival prediction) score, antiviral and immunomodulatory treatments received, inflammatory biomarkers, the need for vasopressors, the thromboprophylaxis regimen received, and respiratory parameters including the length of intubation previous to ECMO and the length of each NIV support (high-flow nasal cannula, continuous positive airway pressure and bi-level positive airway pressure), were also collated in order to assess risk factors for day-90 mortality. The effect of the time lapse between NIV support and VV-ECMO on survival was evaluated using logistic regression and adjusting the association with all factors that were significant in the univariate analysis.
Results: Seventy-two patients finally received VV-ECMO support. At 90 days after commencing VV-ECMO 35 patients (48%) had died and 37 patients (52%) were alive. Multivariable analysis showed that at VV-ECMO initiation, age (p = 0.02), lactate (p = 0.001), and days from initiation of NIV support to starting VV-ECMO (p = 0.04) were all associated with day-90 mortality.
Conclusions: In our small cohort of VV-ECMO patients with COVID-19 associated ARDS, the time spent between initiation of NIV support and VV-ECMO (together with age and lactate) appeared to be a better predictor of mortality than the time between intubation and VV-ECMO.
Keywords: ARDS; COVID-19; Extracorporeal membrane oxygenation; Non-invasive ventilation; Respiratory insufficiency.